Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Clinically relevant biomarkers in targeted radiotherapy.

Stea B, Gordon J.

Clin Exp Metastasis. 2012 Oct;29(7):853-60. doi: 10.1007/s10585-012-9523-z. Epub 2012 Aug 11.

PMID:
22886523
[PubMed - indexed for MEDLINE]
2.

Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.

Lunsford LD, Flickinger JC, Larson D.

Oncologist. 1997;2(1):59-61.

PMID:
10388030
[PubMed - as supplied by publisher]
Free Article
3.

Therapeutic targets in radiotherapy.

Brown JM.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):319-26.

PMID:
11173124
[PubMed - indexed for MEDLINE]
4.

Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: comparative cellular radiosensitivity and hypoxic percentages.

Leith JT, Cook S, Chougule P, Calabresi P, Wahlberg L, Lindquist C, Epstein M.

Acta Neurochir Suppl. 1994;62:18-27. Review.

PMID:
7717130
[PubMed - indexed for MEDLINE]
5.

Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings.

Milas L, Mason KA, Ang KK.

Int J Radiat Biol. 2003 Jul;79(7):539-45. Review.

PMID:
14530163
[PubMed - indexed for MEDLINE]
6.

Predictive factors in radiotherapy for non-small cell lung cancer: present status.

Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P.

Lung Cancer. 2001 Jan;31(1):43-56. Review.

PMID:
11162866
[PubMed - indexed for MEDLINE]
7.

Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites.

Teh BS, Paulino AC, Lu HH, Chiu JK, Richardson S, Chiang S, Amato R, Butler EB, Bloch C.

Technol Cancer Res Treat. 2007 Aug;6(4):347-54.

PMID:
17668943
[PubMed - indexed for MEDLINE]
8.

Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

Vordermark D, Brown JM.

Strahlenther Onkol. 2003 Dec;179(12):801-11. Review.

PMID:
14652668
[PubMed - indexed for MEDLINE]
9.

Translational research offers individually tailored treatments for cancer patients.

Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M.

Cancer J Sci Am. 2000 Jan-Feb;6(1):2-10. Review.

PMID:
10696731
[PubMed - indexed for MEDLINE]
10.

Towards prediction and modulation of treatment response.

Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M.

Radiother Oncol. 1999 Jan;50(1):1-11. Review.

PMID:
10225551
[PubMed - indexed for MEDLINE]
11.

Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.

Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD.

J Clin Oncol. 2005 Aug 20;23(24):5560-7.

PMID:
16110017
[PubMed - indexed for MEDLINE]
Free Article
12.

[Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond].

Teh BS, Paulino A, Butler EB.

Ai Zheng. 2008 Aug;27(8):885-93. Review. Chinese.

PMID:
18710628
[PubMed - indexed for MEDLINE]
13.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
14.

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C.

J Natl Cancer Inst. 2011 Apr 20;103(8):645-61. doi: 10.1093/jnci/djr093. Epub 2011 Apr 4.

PMID:
21464397
[PubMed - indexed for MEDLINE]
Free Article
15.

Hypoxic sensitizer and cytotoxin for head and neck cancer.

Lee DJ, Moini M, Giuliano J, Westra WH.

Ann Acad Med Singapore. 1996 May;25(3):397-404. Review.

PMID:
8876907
[PubMed - indexed for MEDLINE]
16.

Predicting recurrence after radiotherapy in head and neck cancer.

Begg AC.

Semin Radiat Oncol. 2012 Apr;22(2):108-18. doi: 10.1016/j.semradonc.2011.12.002. Review.

PMID:
22385918
[PubMed - indexed for MEDLINE]
17.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
[PubMed - indexed for MEDLINE]
18.

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.

Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA).

Acta Oncol. 2005;44(1):50-8.

PMID:
15848906
[PubMed - indexed for MEDLINE]
19.

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK.

Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2.

PMID:
20119866
[PubMed - indexed for MEDLINE]
20.

Proton radiation therapy for chordomas and chondrosarcomas of the skull base.

Hug EB, Slater JD.

Neurosurg Clin N Am. 2000 Oct;11(4):627-38. Review.

PMID:
11082173
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk